Xtalks
Advertising Services
Toronto, Ontario 9,286 followers
Celebrating 20 years of delivering webinars to FDA and EMA regulated industries. View jobs, webinars, videos, and more.
About us
Always at the forefront of digital media, we strive to connect practitioners with quality content in the most accessible and interactive way possible. Our online communities serve as knowledge hubs and information exchanges, enabling industry professionals to make better, more informed decisions. We manage an ever-evolving portfolio of digital media formats, such as webinars, videos, discussions, virtual events and thought-provoking editorial offerings. Our aim is to better connect practitioners with the content they need and when they need it.
- Website
-
http://www.xtalks.com
External link for Xtalks
- Industry
- Advertising Services
- Company size
- 11-50 employees
- Headquarters
- Toronto, Ontario
- Type
- Privately Held
- Founded
- 2005
- Specialties
- Life Science, Pharmaceuticals, Webinars, Health, Medical Devices, and Food
Locations
-
Primary
Get directions
1235 Bay Street
Suite 802
Toronto, Ontario, CA
Employees at Xtalks
-
Travis Gardiner
Independent Salesforce Consultant | 3 x Salesforce Certified | Salesforce Certified Administrator | ⭐ ⭐ ⭐ Trailhead Ranger | 24x Superbadges |…
-
Sara Hadi, PhD
Life Science Marketer | Communications Editor | Pharmaceutical Marketing | Digital Media | Xtalks!
-
Pauline Frank
Patient Engagement Innovation & Global Health
-
Gabriela Bravo
Global Director, Value Added Services, Life Sciences at Xtalks
Updates
-
🦷 🌍 Oral health disparities continue to impact underserved communities around the world. We spoke to Dr. Maria Ryan, EVP and Chief Clinical Officer at Colgate-Palmolive and Allison Cohen Neale, VP of Public Policy at Henry Schein to gain their insights on overcoming barriers and integrating oral health into broader health policies. Read more: https://buff.ly/3Wc8mYS #Healthcare #HealthDisparities #DentalCare #OralHealth #HealthcareAccess
-
💡 Join EmVenio Research for an informative webinar that revolutionizes hybrid #clinicaltrials with patient-centric solutions, accelerating the development of life-changing therapies. Hybrid and decentralized clinical trials offer flexible options, reducing patient burden, increasing retention, and ensuring a more representative population. Expert speakers, Thad Wolfram and Raj Sharma will explore innovative solutions and key partnerships essential for hybrid clinical trials, sharing insights on how flexibility can propel clinical research forward! ➡️ Learn more + register here: https://buff.ly/4cuqyT0 #PatientCentricity #PatientRecruitment #HybridClinicalTrials #DecentralizedClinicalTrials #PatientCentricTrials
-
-
📊 💊 Our latest blog delves into the top 30 drugs to watch in 2024, leveraging insights from their sales performance in 2023. These meds have not only redefined therapeutic standards but have also showcased impressive sales figures, innovative advancements and expanded indications. Read more here: https://buff.ly/3VNsz5P #TopDrugs2024 #PharmaceuticalTrends #PharmaInsights #HealthcareInnovation
Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data
xtalks.com
-
🍽️ 🧬 The US FDA Foods Program recently released an update on its priority guidance topics for 2024, including guidance on New Dietary Ingredient Notifications and preventive controls for human food. Read more to learn about all the guidance updates: https://buff.ly/45U8teU #FoodSafety #FoodRegulations #GenomeEditing
FDA Foods Program: Key Priority Guidance Updates for 2024
xtalks.com
-
Eli Lilly and Company is finally entering the #Alzheimer’s arena with the FDA approval of its anti-amyloid therapy #Kisunla. Read more about the drug, which will be going up against Biogen and Eisai’s Leqembi: https://buff.ly/3LaoUKj #FDAApproval #AlzheimersDisease #NeurodegenerativeDiseases #BetaAmyloid #AmyloidBeta #AntiAmyloidTherapy #MonoclonalAntibody #EliLilly #Neuroscience #Neurology
Eli Lilly's Kisunla (donanemab) Gets Full FDA Approval After Initial Rejection, Gears Up to Take on Leqembi
xtalks.com
-
The FDA has granted approval to Verona Pharma’s dual #bronchodilator and non-steroidal anti-inflammatory #Ohtuvayre for the treatment of chronic obstructive pulmonary disorder (#COPD). Read more about the approval, which was decades in the making: https://buff.ly/3ztWCI6 #LungDisease #PulmonaryDisease #ChronicLungDiseases
Verona’s COPD Drug Ohtuvayre (ensifentrine) Gets FDA Nod
xtalks.com
-
🚀 Food #IPOs in 2024 have been surprisingly sparse, but three notable companies have made their debut on the stock market so far this year. Read more to learn which food companies have closed IPOs in 2024: https://buff.ly/3W6dqOk #FoodCompanies #FoodIPOs #FoodindustryNews
Food IPOs 2024: A Look at the Companies that Have Gone Public This Year
xtalks.com